Biohackers Have Become Mainstream Who Are They And What Do They Do?

While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...
Fierce Biotech

New in vivo gene editing biotech blossoms from CRISPR pioneer Jennifer Doudna's lab with $82M

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

From Vision To Value: New Book Details The Leadership Model Revolutionizing Real Estate

NEW YORK (November 4, 2025) — Think Bigger, Lead Better: Eight to Great Principles for Organizational Success by Rick ...
Scientific American

Gene Editing Helped One Baby—Could It Help Thousands?

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, durabl ...
The Scientist

Next-Generation CRISPR Nucleases Expand Therapeutic Options

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...